Pub Date : 2026-03-16DOI: 10.1161/circulationaha.125.076777
Junzhong Zou,Xudong Huang,Juan Wu
{"title":"Letter by Zou et al Regarding Article, \"Impacts of Reducing Sitting Time or Increasing Sit-to-Stand Transitions on Blood Pressure and Glucose Regulation in Postmenopausal Women: Three-Arm Randomized Controlled Trial\".","authors":"Junzhong Zou,Xudong Huang,Juan Wu","doi":"10.1161/circulationaha.125.076777","DOIUrl":"https://doi.org/10.1161/circulationaha.125.076777","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"11 1","pages":"e938-e939"},"PeriodicalIF":37.8,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147465178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-16DOI: 10.1161/circulationaha.125.077509
Saibal Kar
{"title":"Response by Kar to Letter Regarding Article, \"Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Controlled Trial\".","authors":"Saibal Kar","doi":"10.1161/circulationaha.125.077509","DOIUrl":"https://doi.org/10.1161/circulationaha.125.077509","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"11 1","pages":"e937"},"PeriodicalIF":37.8,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147465183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-16DOI: 10.1161/circulationaha.125.078657
Sanket S Dhruva
{"title":"Role of High-Dose Influenza Vaccine in Reducing Cardiovascular Risk.","authors":"Sanket S Dhruva","doi":"10.1161/circulationaha.125.078657","DOIUrl":"https://doi.org/10.1161/circulationaha.125.078657","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"60 1","pages":"807-809"},"PeriodicalIF":37.8,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147465180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-16DOI: 10.1161/circulationaha.125.076484
Peng Sun
{"title":"Letter by Sun Regarding Article, \"Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Controlled Trial\".","authors":"Peng Sun","doi":"10.1161/circulationaha.125.076484","DOIUrl":"https://doi.org/10.1161/circulationaha.125.076484","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"59 1","pages":"e936"},"PeriodicalIF":37.8,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147465179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BACKGROUNDHypertrophic cardiomyopathy (HCM), the most common inherited cardiac disorder and a leading cause of sudden cardiac death in young adults, exhibits substantial genetic and clinical heterogeneity. Although sarcomere gene sequence variations account for a major proportion of HCM cases, nearly half of patients lack identifiable genetic defects, implying the involvement of undiscovered mechanisms that may converge on a common pathogenic pathway. However, a unified molecular basis underlying HCM pathogenesis remains undefined.METHODSWe conducted an integrated analysis of hypertrophied interventricular septum tissues from 269 patients with obstructive HCM undergoing surgical myectomy. Targeted sarcomere gene screening, bulk RNA sequencing, and weighted gene coexpression network analysis were used to identify candidate drivers of disease. Cross-species validation was performed using a Myh6 R404Q/+ mouse model. Single-cell RNA sequencing delineated the cellular source of key factors, and biochemical assays and gain- and loss-of-function studies were used to assess their functional relevance. CRLF1 (cytokine receptor-like factor 1) emerged as a candidate mediator and was further evaluated in vitro and in vivo.RESULTSCRLF1, predominantly secreted by activated cardiac fibroblasts, emerged as a key paracrine factor driving cardiomyocyte hypertrophy across patients with genetically heterogeneous HCM. CRLF1 levels were significantly elevated in hypertrophied myocardium and circulation. CRLF1 activated the LIFR (leukemia inhibitory factor receptor)-JAK1/2 (Janus kinase)-STAT3 (signal transducer and activator of transcription 3) signaling cascade to promote hypertrophy in both murine and human HCM models. Genetic ablation of Crlf1 in fibroblasts or pharmacological inhibition of its downstream pathway markedly attenuated disease phenotypes.CONCLUSIONSOur findings uncover a common, nongenetic paracrine mechanism underlying HCM pathogenesis and establish CRLF1 as a promising universal therapeutic target for this heterogeneous disease.
{"title":"CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy.","authors":"Bowen Lin,Jizheng Wang,Can Li,Shuiyun Wang,Meiting Shen,Lingjie Hu,Lei Chen,Fanhong Zhou,Yiqiao Liu,Jian Yang,Mo Zhang,Dong Wang,Guoliang Xu,Bin Zhou,Lei Song,Dan Shi,Yi-Han Chen","doi":"10.1161/circulationaha.125.075290","DOIUrl":"https://doi.org/10.1161/circulationaha.125.075290","url":null,"abstract":"BACKGROUNDHypertrophic cardiomyopathy (HCM), the most common inherited cardiac disorder and a leading cause of sudden cardiac death in young adults, exhibits substantial genetic and clinical heterogeneity. Although sarcomere gene sequence variations account for a major proportion of HCM cases, nearly half of patients lack identifiable genetic defects, implying the involvement of undiscovered mechanisms that may converge on a common pathogenic pathway. However, a unified molecular basis underlying HCM pathogenesis remains undefined.METHODSWe conducted an integrated analysis of hypertrophied interventricular septum tissues from 269 patients with obstructive HCM undergoing surgical myectomy. Targeted sarcomere gene screening, bulk RNA sequencing, and weighted gene coexpression network analysis were used to identify candidate drivers of disease. Cross-species validation was performed using a Myh6 R404Q/+ mouse model. Single-cell RNA sequencing delineated the cellular source of key factors, and biochemical assays and gain- and loss-of-function studies were used to assess their functional relevance. CRLF1 (cytokine receptor-like factor 1) emerged as a candidate mediator and was further evaluated in vitro and in vivo.RESULTSCRLF1, predominantly secreted by activated cardiac fibroblasts, emerged as a key paracrine factor driving cardiomyocyte hypertrophy across patients with genetically heterogeneous HCM. CRLF1 levels were significantly elevated in hypertrophied myocardium and circulation. CRLF1 activated the LIFR (leukemia inhibitory factor receptor)-JAK1/2 (Janus kinase)-STAT3 (signal transducer and activator of transcription 3) signaling cascade to promote hypertrophy in both murine and human HCM models. Genetic ablation of Crlf1 in fibroblasts or pharmacological inhibition of its downstream pathway markedly attenuated disease phenotypes.CONCLUSIONSOur findings uncover a common, nongenetic paracrine mechanism underlying HCM pathogenesis and establish CRLF1 as a promising universal therapeutic target for this heterogeneous disease.","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"28 1","pages":"845-862"},"PeriodicalIF":37.8,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147465181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-13DOI: 10.1161/cir.0000000000001429
Roger S Blumenthal,Pamela B Morris,
{"title":"Clinical Guidelines as a Continuous Work in Progress: Moving at the Speed of Science.","authors":"Roger S Blumenthal,Pamela B Morris, ","doi":"10.1161/cir.0000000000001429","DOIUrl":"https://doi.org/10.1161/cir.0000000000001429","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"411 1","pages":""},"PeriodicalIF":37.8,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-13DOI: 10.1161/cir.0000000000001423
,Roger S Blumenthal,Pamela B Morris,Mario Gaudino,Heather M Johnson,Timothy S Anderson,Vera A Bittner,Ron Blankstein,LaPrincess C Brewer,Leslie Cho,Sarah D de Ferranti,Eugenia Gianos,Ty J Gluckman,Kristen F Gradney,Ijeoma Isiadinso,Donald M Lloyd-Jones,Joel C Marrs,Seth S Martin,Kellie H McLain,Laxmi S Mehta,Samia Mora,Wudeneh M Mulugeta,Pradeep Natarajan,Ann Marie Navar,Carl E Orringer,Tamar S Polonsky,Harmony R Reynolds,Joseph J Saseen,Michael D Shapiro,Daniel E Soffer,Sheila A Tynes,Chloé D Villavaso,Salim S Virani,John T Wilkins
AIMThe "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia" retires and replaces the "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol."METHODSA comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline.STRUCTUREThe focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).
{"title":"2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","authors":" ,Roger S Blumenthal,Pamela B Morris,Mario Gaudino,Heather M Johnson,Timothy S Anderson,Vera A Bittner,Ron Blankstein,LaPrincess C Brewer,Leslie Cho,Sarah D de Ferranti,Eugenia Gianos,Ty J Gluckman,Kristen F Gradney,Ijeoma Isiadinso,Donald M Lloyd-Jones,Joel C Marrs,Seth S Martin,Kellie H McLain,Laxmi S Mehta,Samia Mora,Wudeneh M Mulugeta,Pradeep Natarajan,Ann Marie Navar,Carl E Orringer,Tamar S Polonsky,Harmony R Reynolds,Joseph J Saseen,Michael D Shapiro,Daniel E Soffer,Sheila A Tynes,Chloé D Villavaso,Salim S Virani,John T Wilkins","doi":"10.1161/cir.0000000000001423","DOIUrl":"https://doi.org/10.1161/cir.0000000000001423","url":null,"abstract":"AIMThe \"2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia\" retires and replaces the \"2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.\"METHODSA comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline.STRUCTUREThe focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"54 1","pages":""},"PeriodicalIF":37.8,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-13DOI: 10.1161/circulationaha.126.079538
Karol E Watson,Gregg C Fonarow
{"title":"The 2026 American College of Cardiology/American Heart Association Multisociety Guideline on the Management of Dyslipidemia: A More Precise-But More Complicated-Framework for Atherosclerotic Cardiovascular Disease Prevention and Treatment.","authors":"Karol E Watson,Gregg C Fonarow","doi":"10.1161/circulationaha.126.079538","DOIUrl":"https://doi.org/10.1161/circulationaha.126.079538","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"34 1","pages":""},"PeriodicalIF":37.8,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147446936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-10Epub Date: 2026-02-09DOI: 10.1161/CIR.0000000000001391
Lili Zhang, Cezar Iliescu, Maros Ferencik, Victoria Finamore, Craig Beavers, Amit R Patel, Brian Ghoshhajra, Sarah Milgrom, Susan Dent, Lauren A Baldassarre, Iris Z Jaffe, Juan Lopez-Mattei
There is an emerging convergence between atherosclerotic cardiovascular disease and cancer, driven by shared risk factors and overlapping pathophysiologic mechanisms. Traditional factors, such as smoking, aging, obesity, hypertension, and diabetes, alongside novel markers, such as clonal hematopoiesis of indeterminate potential, not only predispose individuals to both malignancies and coronary atherosclerosis but also amplify the risk of cardiotoxicity from cancer therapies. Inflammatory processes play a central role in atherogenesis, a process further accelerated by oncologic treatments-including chemotherapy (eg, anthracyclines, 5-fluorouracil), targeted and hormone therapies (eg, tyrosine kinase inhibitors, androgen deprivation, aromatase inhibitors), immune checkpoint inhibitors, and radiation therapy (RT)-that contribute to endothelial dysfunction and plaque instability. This scientific statement synthesizes the evidence on the interplay between cancer and coronary atherosclerosis, highlighting advances in noninvasive imaging modalities (ie, cardiac CT, nuclear imaging, cardiac magnetic resonance, echocardiography) for early detection, risk stratification, and surveillance of coronary artery disease in oncologic populations, and examines the role of invasive imaging techniques in guiding revascularization decisions. Given the elevated bleeding and thrombotic risks in these patients, individualized management of post-percutaneous coronary intervention medications and abbreviated dual antiplatelet therapy regimens is emphasized. This scientific statement also addresses knowledge gaps and reinforces the need for more evidence to improve risk stratification for atherosclerotic cardiovascular disease in patients with cancer. The shared pathobiology between coronary atherosclerosis and cancer necessitates an integrated, multidisciplinary approach to screening, diagnosis, and management.
{"title":"Coronary Atherosclerosis in Patients With Cancer and Survivors: A Scientific Statement From the American Heart Association.","authors":"Lili Zhang, Cezar Iliescu, Maros Ferencik, Victoria Finamore, Craig Beavers, Amit R Patel, Brian Ghoshhajra, Sarah Milgrom, Susan Dent, Lauren A Baldassarre, Iris Z Jaffe, Juan Lopez-Mattei","doi":"10.1161/CIR.0000000000001391","DOIUrl":"10.1161/CIR.0000000000001391","url":null,"abstract":"<p><p>There is an emerging convergence between atherosclerotic cardiovascular disease and cancer, driven by shared risk factors and overlapping pathophysiologic mechanisms. Traditional factors, such as smoking, aging, obesity, hypertension, and diabetes, alongside novel markers, such as clonal hematopoiesis of indeterminate potential, not only predispose individuals to both malignancies and coronary atherosclerosis but also amplify the risk of cardiotoxicity from cancer therapies. Inflammatory processes play a central role in atherogenesis, a process further accelerated by oncologic treatments-including chemotherapy (eg, anthracyclines, 5-fluorouracil), targeted and hormone therapies (eg, tyrosine kinase inhibitors, androgen deprivation, aromatase inhibitors), immune checkpoint inhibitors, and radiation therapy (RT)-that contribute to endothelial dysfunction and plaque instability. This scientific statement synthesizes the evidence on the interplay between cancer and coronary atherosclerosis, highlighting advances in noninvasive imaging modalities (ie, cardiac CT, nuclear imaging, cardiac magnetic resonance, echocardiography) for early detection, risk stratification, and surveillance of coronary artery disease in oncologic populations, and examines the role of invasive imaging techniques in guiding revascularization decisions. Given the elevated bleeding and thrombotic risks in these patients, individualized management of post-percutaneous coronary intervention medications and abbreviated dual antiplatelet therapy regimens is emphasized. This scientific statement also addresses knowledge gaps and reinforces the need for more evidence to improve risk stratification for atherosclerotic cardiovascular disease in patients with cancer. The shared pathobiology between coronary atherosclerosis and cancer necessitates an integrated, multidisciplinary approach to screening, diagnosis, and management.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"e916-e933"},"PeriodicalIF":38.6,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-10Epub Date: 2026-03-09DOI: 10.1161/CIR.0000000000001427
Charlotte E Verrall, Joseph Y M Yang, Jian Chen, Adrian Schembri, Yves d'Udekem, Diana Zannino, Nadine A Kasparian, Karin du Plessis, Stuart M Grieve, Thomas Welton, Belinda Barton, Thomas L Gentles, David S Celermajer, Chantal Attard, Kathryn Rice, Julian Ayer, Simone Mandelstam, David S Winlaw, Mark T Mackay, Rachael Cordina
{"title":"Correction to: Neurocognitive Dysfunction and Smaller Brain Volumes in Adolescents and Adults With a Fontan Circulation.","authors":"Charlotte E Verrall, Joseph Y M Yang, Jian Chen, Adrian Schembri, Yves d'Udekem, Diana Zannino, Nadine A Kasparian, Karin du Plessis, Stuart M Grieve, Thomas Welton, Belinda Barton, Thomas L Gentles, David S Celermajer, Chantal Attard, Kathryn Rice, Julian Ayer, Simone Mandelstam, David S Winlaw, Mark T Mackay, Rachael Cordina","doi":"10.1161/CIR.0000000000001427","DOIUrl":"https://doi.org/10.1161/CIR.0000000000001427","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"153 10","pages":"e935"},"PeriodicalIF":38.6,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：